Atria Investments Inc Takes $269,000 Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

Atria Investments Inc purchased a new position in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) during the 3rd quarter, Holdings Channel.com reports. The firm purchased 4,836 shares of the biopharmaceutical company’s stock, valued at approximately $269,000.

A number of other hedge funds have also added to or reduced their stakes in the company. Capital Performance Advisors LLP acquired a new stake in shares of Ultragenyx Pharmaceutical in the 3rd quarter valued at $107,000. Principal Financial Group Inc. boosted its stake in Ultragenyx Pharmaceutical by 740.0% in the third quarter. Principal Financial Group Inc. now owns 86,440 shares of the biopharmaceutical company’s stock valued at $4,802,000 after buying an additional 76,150 shares in the last quarter. Emerald Advisers LLC grew its position in Ultragenyx Pharmaceutical by 17.1% in the third quarter. Emerald Advisers LLC now owns 569,798 shares of the biopharmaceutical company’s stock valued at $31,652,000 after acquiring an additional 83,116 shares during the last quarter. Emerald Mutual Fund Advisers Trust raised its stake in Ultragenyx Pharmaceutical by 9.9% during the third quarter. Emerald Mutual Fund Advisers Trust now owns 429,302 shares of the biopharmaceutical company’s stock worth $23,848,000 after acquiring an additional 38,778 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. lifted its holdings in shares of Ultragenyx Pharmaceutical by 81.5% in the third quarter. China Universal Asset Management Co. Ltd. now owns 17,726 shares of the biopharmaceutical company’s stock worth $985,000 after acquiring an additional 7,960 shares during the last quarter. 97.67% of the stock is owned by institutional investors.

Ultragenyx Pharmaceutical Price Performance

Shares of RARE stock opened at $47.24 on Friday. Ultragenyx Pharmaceutical Inc. has a one year low of $37.02 and a one year high of $60.37. The business’s 50 day simple moving average is $53.37 and its 200 day simple moving average is $48.36. The stock has a market capitalization of $4.36 billion, a PE ratio of -7.11 and a beta of 0.58.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its quarterly earnings data on Tuesday, November 5th. The biopharmaceutical company reported ($1.40) earnings per share for the quarter, topping the consensus estimate of ($1.45) by $0.05. Ultragenyx Pharmaceutical had a negative net margin of 106.93% and a negative return on equity of 187.12%. The company had revenue of $139.49 million during the quarter, compared to analysts’ expectations of $135.28 million. During the same period in the prior year, the company posted ($2.23) earnings per share. Ultragenyx Pharmaceutical’s revenue for the quarter was up 42.3% compared to the same quarter last year. As a group, research analysts expect that Ultragenyx Pharmaceutical Inc. will post -6.21 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the stock. Wedbush lifted their price target on shares of Ultragenyx Pharmaceutical from $43.00 to $46.00 and gave the company a “neutral” rating in a report on Friday, August 2nd. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $116.00 target price on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, November 6th. JPMorgan Chase & Co. dropped their price target on Ultragenyx Pharmaceutical from $105.00 to $102.00 and set an “overweight” rating for the company in a research note on Thursday. The Goldman Sachs Group boosted their price objective on Ultragenyx Pharmaceutical from $67.00 to $76.00 and gave the stock a “buy” rating in a research report on Friday, August 2nd. Finally, HC Wainwright increased their target price on Ultragenyx Pharmaceutical from $82.00 to $95.00 and gave the company a “buy” rating in a research report on Wednesday, November 6th. Two analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. According to data from MarketBeat.com, Ultragenyx Pharmaceutical presently has a consensus rating of “Moderate Buy” and a consensus target price of $87.46.

Insiders Place Their Bets

In other news, CEO Emil D. Kakkis sold 20,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $55.85, for a total transaction of $1,117,000.00. Following the completion of the sale, the chief executive officer now owns 2,223,985 shares of the company’s stock, valued at $124,209,562.25. This trade represents a 0.89 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CFO Howard Horn sold 7,465 shares of the business’s stock in a transaction on Thursday, October 10th. The shares were sold at an average price of $52.76, for a total transaction of $393,853.40. Following the transaction, the chief financial officer now owns 92,301 shares in the company, valued at $4,869,800.76. The trade was a 7.48 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 27,556 shares of company stock worth $1,515,967. Company insiders own 5.80% of the company’s stock.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.